Yoshiaki Murakami

Yoshiaki Murakami

Auto-generated profile, based on publicly available information

Yoshiaki Murakami

Department of Surgery, Graduate School of Biochemical and Health Sciences, Hiroshima University, Hiroshima, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2010 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
YMYoshiaki Murakami
Yoshiaki Murakami
KUKenichiro Uemura
Kenichiro Uemura
TSTakeshi Sudo
Takeshi Sudo
YHYasushi Hashimoto
Yasushi Hashimoto
ANAkira Nakashima
Akira Nakashima
TSTaijiro Sueda
Taijiro Sueda

1 August 2010 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
YMYoshiaki Murakami
Yoshiaki Murakami
KUKenichiro Uemura
Kenichiro Uemura
TSTakeshi Sudo
Takeshi Sudo
YHYasuo Hayashidani
Yasuo Hayashidani
YHYasushi Hashimoto
Yasushi Hashimoto
TSTaijiro Sueda
Taijiro Sueda
This study evaluated the prognostic significance of the number of metastatic lymph nodes and the ratio of metastatic nodes to total number of examined lymph nodes (lymph node ratio, LNR) after resection of pancreatic carcinoma. Records of 119 consecutive patients with pancreatic ductal carcinoma, who underwent R0 or R1 pancreatectomy with regional node dissection, were reviewed retrospectively. Clinical factors, pathologic factors including number of metastatic nodes and LNR, and survival were analyzed by univariate and multivariate analyses. Overall survival rates were 78%, 28%, and 20% at 1, 3, and 5 years, respectively. The median numbers of evaluated lymph nodes and involved nodes were 28 and 3, respectively. Univariate analysis revealed that tumor location, postoperative adjuvant chemotherapy, tumor differentiation, choledochal invasion, portal or splenic vein invasion, extrapancreatic nerve plexus invasion, resection margin status, node status, number of involved nodes, LNR, International Union against Cancer (UICC) pT factor, and UICC stage correlated significantly (p < 0.05) with increased survival. By multivariate analysis, negative node metastasis (p = 0.008) and 0 or 1 involved node (p = 0.004), but not LNR, correlated independently with longer survival. The 1-, 3-, and 5-year survival rates of patients with 0 or 1 metastatic node and patients with 2 or more metastatic nodes were 91%, 48%, and 40% and 66%, 10%, and 0%, respectively. The number of metastatic nodes, but not LNR, is one of the most powerful prognostic factors after resection of pancreatic carcinoma.

15 April 2015 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
YMY Murakami
Y Murakami
SSS Satoi
S Satoi
FMF Motoi
F Motoi
MSM Sho
M Sho
MKM Kawai
M Kawai
M(Multicentre Study Group of Pancreatobiliary Surgery (MSG-PBS)
Multicentre Study Group of Pancreatobiliary Surgery (MSG-PBS)

2 February 2007 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
YMYoshiaki Murakami
Yoshiaki Murakami
KUKenichiro Uemura
Kenichiro Uemura
YHYasuo Hayashidani
Yasuo Hayashidani
TSTakeshi Sudo
Takeshi Sudo
YHYasushi Hashimoto
Yasushi Hashimoto
TSTaijiro Sueda
Taijiro Sueda

1 December 2009 in Annals of Surgery
Verified
Journal Article
Closed access
YMYoshiaki Murakami
Yoshiaki Murakami
KUKenichiro Uemura
Kenichiro Uemura
TSTakeshi Sudo
Takeshi Sudo
YHYasuo Hayashidani
Yasuo Hayashidani
YHYasushi Hashimoto
Yasushi Hashimoto
TSTaijiro Sueda
Taijiro Sueda
The aim of this study was to evaluate the efficacy of adjuvant gemcitabine plus S-1 chemotherapy after aggressive surgical resection for advanced biliary carcinoma. No effective adjuvant therapy for advanced biliary carcinoma has been reported although its prognosis is extremely poor. Medical records were reviewed for 103 patients with International Union Against Cancer (UICC) stage II biliary carcinoma who underwent aggressive surgical resection. About 50 patients received 10 cycles of adjuvant gemcitabine plus S-1 chemotherapy and 53 patients did not. Clinicopathological factors and patient survival were compared between the 2 groups using univariate and multivariate analysis. A cycle of chemotherapy consisted of intravenous gemcitabine 700 mg/m2 on day 1 and oral S-1 50 mg/m2 for 7 consecutive days, followed by a 1-week break from chemotherapy. Patient demographics, tumor characteristics, and surgical procedures did not differ between the 2 groups. Aggressive surgical procedures including major hepatectomy or pancreatoduodenectomy were performed for 94 of 103 patients. In the chemotherapy group, 37 patients (74%) were given the full number of 10 cycles. The use of postoperative adjuvant chemotherapy (P < 0.001) and surgical margin status (P = 0.003) were independently associated with long-term survival by multivariate analysis. Five-year survival rates of patients who did or did not receive postoperative adjuvant chemotherapy were 57% and 24%, respectively (P < 0.001). Toxicity during chemotherapy was mild. Adjuvant gemcitabine plus S-1 chemotherapy may be one of several factors contributing to improved outcomes after aggressive surgical resection of advanced biliary carcinoma in recent years.

1 August 2009 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
YMYoshiaki Murakami
Yoshiaki Murakami
KUKenichiro Uemura
Kenichiro Uemura
TSTakeshi Sudo
Takeshi Sudo
YHYasuo Hayashidani
Yasuo Hayashidani
YHYasushi Hashimoto
Yasushi Hashimoto
TSTaijiro Sueda
Taijiro Sueda